Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

216 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. Sandborn WJ, et al. N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572. N Engl J Med. 2012. PMID: 23075178 Clinical Trial.
Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.
Panaccione R, Fedorak RN, Aumais G, Bernstein CN, Bitton A, Croitoru K, Enns R, Feagan B, Fishman M, Greenberg G, Griffiths A, Marshall JK, Rasul I, Sadowski D, Seidman E, Steinhart H, Sutherland L, Walli E, Wild G, Williams CN, Zachos M; Canadian Association of Gastroenterology. Panaccione R, et al. Can J Gastroenterol. 2004 Aug;18(8):503-8. doi: 10.1155/2004/670161. Can J Gastroenterol. 2004. PMID: 15372114 No abstract available.
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators. Khanna R, et al. Among authors: greenberg gr. Lancet. 2015 Nov 7;386(10006):1825-34. doi: 10.1016/S0140-6736(15)00068-9. Epub 2015 Sep 3. Lancet. 2015. PMID: 26342731 Clinical Trial.
216 results